LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LUCD LUCID DIAGNOSTICS INC.

Market Closed 04-02 16:00:00 EDT

1.14

-0.01

-0.87%

盘后1.14

+0.000.00%

17:30 EDT

High1.16	Low1.12	Vol299.00K
Open1.12	D1 Closing1.15	Amplitude3.48%
Mkt Cap201.72M	Tradable Cap124.45M	Total Shares176.95M
T/O341.07K	T/O Rate0.27%	Tradable Shares109.16M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LUCD","market":"US","secType":"STK","nameCN":"LUCID DIAGNOSTICS INC.","latestPrice":1.14,"timestamp":1775160000000,"preClose":1.15,"halted":0,"volume":298995,"hourTrading":{"tag":"盘后","latestPrice":1.14,"preClose":1.14,"latestTime":"17:30 EDT","volume":3118,"amount":3554.96,"timestamp":1775165438281,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.008695652173913052,"floatShares":109163095,"shares":176945972,"eps":-0.692213,"marketStatus":"Market Closed","change":-0.01,"latestTime":"04-02 16:00:00 EDT","open":1.12,"high":1.16,"low":1.12,"amount":341066.048259,"amplitude":0.034783,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.692213,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775462400000},"marketStatusCode":7,"adr":0,"listingDate":1634184000000,"exchange":"NASDAQ","adjPreClose":1.15,"preHourTrading":{"tag":"盘前","latestPrice":1.13,"preClose":1.15,"latestTime":"07:14 EDT","volume":3,"amount":3.4759002,"timestamp":1775128449659,"change":-0.02,"changeRate":-0.017391,"amplitude":0.039913},"postHourTrading":{"tag":"盘后","latestPrice":1.14,"preClose":1.14,"latestTime":"17:30 EDT","volume":3118,"amount":3554.96,"timestamp":1775165438281,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.45494271946522374},"requestUrl":"/m/hq/s/LUCD","defaultTab":"news","newsList":[{"id":"2624506671","title":"Press Release: PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2624506671","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624506671?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:01","pubTimestamp":1775131260,"startTime":"0","endTime":"0","summary":"Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio.Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging technology recently licensed from Duke University.NEW YORK, April 2, 2026 /PRNewswire/ -- PAVmed Inc.  , a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has appointed medical technology industry veteran Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices to oversee the development and commercialization of PAVmed's current and future medical device portfolio.\"PAVmed has already established a strong foundation with its existing medi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","PAVM","LUCD","BK4022","R","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623175383","title":"PAVmed Inc - Q4 2025 Non-Gaap Adj Loss $0.9 Mln, $1.05 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2623175383","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623175383?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:07","pubTimestamp":1774872423,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nFWN40I0Q5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAVM","LUCD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623127473","title":"Press Release: PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2623127473","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623127473?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:00","pubTimestamp":1774872000,"startTime":"0","endTime":"0","summary":"PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership. Veris Health advanced strategic partnership with OSU and progressed implantable physiological monitor toward FDA submission. Lucid Diagnostics expanded EsoGuard healthcare system access and clinical evidence base. Conference call and webcast to be held today, March 30, at 8:30 AM EST. NEW YORK, March 30, 2026 /PRNewswire/ -- PAVmed Inc.  , a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc.   and Veris Health Inc. , and reported financial results for the fourth quarter and year ended December 31, 2025.The webcast will take place on Monday, March 30, 2026, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.  Alternatively, to access the conference call by tel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4022","BK4232","LCDL","LCIZ","BK4596","LUCD","PAVM","BK4555","R","LCID","BK4082","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622578891","title":"Lucid Diagnostics Inc: May Offer and Sell Shares of Common Stock of up to $25 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622578891","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622578891?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:02","pubTimestamp":1774558967,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E12D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LUCD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622634698","title":"Lucid Diagnostics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622634698","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622634698?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:32","pubTimestamp":1774531932,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics Inc reports results for the quarter ended December 31 - Earnings SummaryLucid Diagnostics Inc LUCD.OQ reported a quarterly adjusted loss of 10 cents per share for the quarter ended D","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL8N40E1BP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD","PAVM","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622850574","title":"Canaccord Genuity Sticks to Its Buy Rating for Lucid Diagnostics (LUCD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622850574","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622850574?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:37","pubTimestamp":1774528659,"startTime":"0","endTime":"0","summary":"In a report released today, Kyle Mikson CFA from Canaccord Genuity maintained a Buy rating on Lucid Diagnostics, with a price target of $3.00. Acco...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-its-buy-rating-for-lucid-diagnostics-lucd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-its-buy-rating-for-lucid-diagnostics-lucd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LUCD","LCID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622852446","title":"Press Release: Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622852446","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622852446?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:00","pubTimestamp":1774526400,"startTime":"0","endTime":"0","summary":"Processed 3,664 EsoGuard tests and recognized 4Q25 revenue of $1.5 million. Expanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world experience of esophageal precancer detection. Conference call and webcast to be held today, March 26, at 8:30 AM EST. NEW YORK, March 26, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.   a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc.  , today provided a business update for the Company and reported financial results for the fourth quarter and full year ended December 31, 2025.The webcast will take place on Thursday, March 26, 2026, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.  Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4555","LCDL","LUCD","R","BK4551","LCID","LCIZ","BK4082","BK4022","BK4099","BK4596"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622400784","title":"Lucid Diagnostics FY2025 operating loss widens to $58 million; revenue rises 9.3% to $4.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622400784","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622400784?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:57","pubTimestamp":1774472229,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025.Reported revenue of USD 4.7 million, up 9.3%, driven mainly by higher consideration received for EsoGuard tests.Cost of revenue was USD 6.7 million, down 5.6%, primarily reflecting lower manufacturing costs for EsoCheck devices and EsoGuard tests.Cash used in operations was USD 46.5 million.Ended the year with cash on hand of USD 34.7 million.Business updates included an 18-month real-world analysis covering about 12,000 patients.Business updates also included a U.S. Department of Veterans Affairs contract award for EsoGuard.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to gener","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL2gf0bk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD","BK4082","PAVM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621906227","title":"Lucid Diagnostics Inc  expected to post a loss of 10 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2621906227","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621906227?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:43","pubTimestamp":1774356185,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics Inc  expected to post a loss of10cents a share - Earnings Preview Lucid Diagnostics Inc LUCD.OQ LUCD.O is expected to  show a rise in quarterly revenue when it reports  results on Ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL8N40C1E8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","PAVM","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618132760","title":"Lucid Diagnostics schedules fourth-quarter and full-year 2025 business update call and webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2618132760","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618132760?lang=en_us&edition=fundamental","pubTime":"2026-03-12 21:10","pubTimestamp":1773321026,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics will hold a fourth quarter and full year 2025 business update conference call and webcast on March 26, 2026, at 8:30 AM ET. The webcast will be available at luciddx.com. Lishan Aklog will provide a business update during the call. Dennis McGrath will discuss fourth quarter 2025 financial results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief on March 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL1YXbK3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAVM","BK4082","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608336480","title":"Press Release: PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2608336480","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608336480?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:01","pubTimestamp":1770210060,"startTime":"0","endTime":"0","summary":"Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local coverage determination. Series D Preferred Stock convertible into common stock subject to stockholder approval at an upcoming special meeting. Proceeds used to redeem and retire all previously outstanding convertible securities, eliminating a significant legacy capital structure overhang. The Company used the proceeds from these financings, consisting of a $22.3 million cash payment and the $15 million long-term senior secured note, to redeem all outstanding shares of its Series C Convertible Preferred Stock, and fully retire its outstanding convertible debt. The remaining $7.7 million in net cash proceeds will be available for general working capital purposes. In total, assuming exercise of the associated warrants upon publication of a positive EsoGuard LCD and conversion of the Series","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4022","LUCD","BK4232","PAVM","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605403839","title":"Individual investors among Lucid Diagnostics Inc.'s (NASDAQ:LUCD) largest stockholders and were hit after last week's 14% price drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2605403839","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605403839?lang=en_us&edition=fundamental","pubTime":"2026-01-23 18:39","pubTimestamp":1769164754,"startTime":"0","endTime":"0","summary":"Key Insights Lucid Diagnostics' significant individual investors ownership suggests that the key decisions are...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-lucd/lucid-diagnostics/news/individual-investors-among-lucid-diagnostics-incs-nasdaqlucd","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-lucd/lucid-diagnostics/news/individual-investors-among-lucid-diagnostics-incs-nasdaqlucd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QYLD","JEPQ","BK4099","TSYW.SI","USJW.SI","SQQQ","TQQQ","QQQE","NQmain","GPIQ","BK4551","LCID","QYLG","QQQJ","BK4082","PSQ",".IXIC","MNQmain","NVIW.SI","USAW.SI","QLD","BK4596","BK4555","QID","QQQY","LUCD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2605497182","title":"What's Going On With PAVmed Shares Thursday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2605497182","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605497182?lang=en_us&edition=fundamental","pubTime":"2026-01-22 22:23","pubTimestamp":1769091780,"startTime":"0","endTime":"0","summary":"PAVmed shares pull back Thursday, possibly retracing recent gains on news its subsidiary, Lucid Diagnostics secured a contract","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/22/benzingaai2023-modern-computer-screen-wi.png?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/22/benzingaai2023-modern-computer-screen-wi.png?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/50067878/whats-going-on-with-pavmed-shares-thursday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/50067878/whats-going-on-with-pavmed-shares-thursday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["SMA","BK4082","PAVM","BK4217","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605867214","title":"BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2605867214","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605867214?lang=en_us&edition=fundamental","pubTime":"2026-01-21 23:49","pubTimestamp":1769010597,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers CompaniesEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL6N3YM11M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HAL","SLB","CNX","KHC","DXC","LUCD","UAL","TDY","CDE","LXRX","IE00B29SXL02.USD","LBRT","LU2430703095.HKD","TFC","IE00BBT3K403.USD","NEM","BK4141","ALB","AMBQ","LPTH","OCUL","PLD","SCHW","BKR","EXE","INTC","LNG","LSTA","AVR","NNE","WMB","GM","BK4534","CBIO","HL","BK4533","F","LU0154245673.USD","TRV","NATH","JNJ","LU0985481810.HKD","ALGS","ROCK","BIOA","OCGN","IE00B775SV38.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2605483858","title":"BUZZ-U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s Famous","url":"https://stock-news.laohu8.com/highlight/detail?id=2605483858","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605483858?lang=en_us&edition=fundamental","pubTime":"2026-01-21 22:25","pubTimestamp":1769005524,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s FamousEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL6N3YM0P9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","HL","RIO.AU","LUCD","CDE","FCX","PAVM","BKR","LU0417517546.SGD","LU1066051811.HKD","LU2272731782.SGD","TRV","IE0004091025.USD","LU2463526074.USD","TDY","LU1201861165.SGD","CBIO","JNJ","LU0347712357.USD","LU2272731600.USD","RIO.UK","LXRX","LU2362540622.SGD","SLB","NFLX","HAL","IE00BLSP4452.SGD","BHP.AU","NATH","LU1023059063.AUD","LU0130103400.USD","SG9999002224.SGD","LPTH","OCUL","LU0079474960.USD","UAL","ALB","ROCK","TEL","LBRT","BK4145","ARM","SCHW","NEM","AVR","TFC","SG9999002232.USD","KHC","PLD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605089488","title":"PAVmed Subsidiary Lucid Diagnostics Wins US Department of Veterans Affairs Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2605089488","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605089488?lang=en_us&edition=fundamental","pubTime":"2026-01-21 22:22","pubTimestamp":1769005336,"startTime":"0","endTime":"0","summary":"PAVmed  subsidiary Lucid Diagnostics  said Wednesday it won a contract from the US Department of Veterans Affairs for its EsoGuard esophageal DNA test for esophageal precancer testing.Financial terms of the contract were not disclosed.The contract includes pre-negotiated pricing for the test that matches the established Medicare payment rate determined by the Centers for Medicare & Medicaid Services, enabling access through a single, national procurement framework, the company said.Shares of PAVmed and Lucid Diagnostics were up 180% and 29% respectively in recent premarket activity Wednesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4596","LUCD","BK4099","BK4551","PAVM","LCID","BK4082","BK4555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605310001","title":"Why Are PAVmed (PAVM) & Lucid Diagnostics (LUCD) Stocks Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2605310001","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605310001?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:49","pubTimestamp":1769003351,"startTime":"0","endTime":"0","summary":"PAVmed stock gained on Wednesday after the company announced a contract with the VA.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-are-pavmed-pavm-lucid-diagnostics-lucd-stocks-up-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-are-pavmed-pavm-lucid-diagnostics-lucd-stocks-up-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","PAVM","BK4099","BK4082","BK4596","BK4555","LUCD","LCID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605107708","title":"BUZZ-Lucid Diagnostics rises after winning VA contract for cancer test","url":"https://stock-news.laohu8.com/highlight/detail?id=2605107708","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605107708?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:29","pubTimestamp":1769002199,"startTime":"0","endTime":"0","summary":"BUZZ-Lucid Diagnostics rises after winningVA contract for cancer test** Shares of cancertest developer Lucid Diagnostics LUCD.O rise 3.31% to $1.25 premarket** Co says it has secured a U.S. Veterans Affairs contract for EsoGuard, its test that checks for DNA changes linked to early esophageal cancer** Esophageal cancer often begins as damage from longterm heartburn and EsoGuard uses a quick office procedure to collect cells and screen for these changes, per LUCD** Says VA hospitals and clinics nationwide can now buy the test at Medicarematched pricing, giving more than 9 million people access to early esophageal cancer screening ** LUCD gained ~33% in 2025","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL4N3YM1AU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD","PAVM","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605102444","title":"Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for Esoguard®","url":"https://stock-news.laohu8.com/highlight/detail?id=2605102444","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605102444?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:01","pubTimestamp":1769000506,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nFWN3YM0KS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAVM","BK4082","LUCD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595907137","title":"BRIEF-PAVmed Announces Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2595907137","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595907137?lang=en_us&edition=fundamental","pubTime":"2025-12-30 22:06","pubTimestamp":1767103584,"startTime":"0","endTime":"0","summary":"BRIEF-PAVmed Announces Reverse Stock SplitDec 30 (Reuters) - PAVmed PAVM.O:PAVMED ANNOUNCES REVERSE STOCK SPLITPAVMED INC: TO CONDUCT 1-FOR-30 REVERSE STOCK SPLIT OF ITS COMMON STOCKPAVMED INC - REVER","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nTUA6VYH1Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD","BK4082","PAVM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.luciddx.com","stockEarnings":[{"period":"1week","weight":-0.0087},{"period":"1month","weight":-0.2138},{"period":"3month","weight":0.0179},{"period":"6month","weight":0.0962},{"period":"1year","weight":-0.2245},{"period":"ytd","weight":0.0459}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.035074},{"month":2,"riseRate":0.8,"avgChangeRate":0.165426},{"month":3,"riseRate":0.4,"avgChangeRate":-0.121674},{"month":4,"riseRate":0.4,"avgChangeRate":-0.075862},{"month":5,"riseRate":0.5,"avgChangeRate":0.04431},{"month":6,"riseRate":0.25,"avgChangeRate":-0.075357},{"month":7,"riseRate":0.5,"avgChangeRate":0.031793},{"month":8,"riseRate":0.75,"avgChangeRate":0.032951},{"month":9,"riseRate":0.25,"avgChangeRate":-0.178841},{"month":10,"riseRate":1,"avgChangeRate":0.186111},{"month":11,"riseRate":0.4,"avgChangeRate":-0.040647},{"month":12,"riseRate":0.2,"avgChangeRate":-0.154424}],"exchange":"NASDAQ","name":"LUCID DIAGNOSTICS INC.","nameEN":"LUCID DIAGNOSTICS INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LUCID DIAGNOSTICS INC.(LUCD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LUCID DIAGNOSTICS INC.,LUCD,LUCID DIAGNOSTICS INC.股票,LUCID DIAGNOSTICS INC.股票老虎,LUCID DIAGNOSTICS INC.股票老虎国际,LUCID DIAGNOSTICS INC.行情,LUCID DIAGNOSTICS INC.股票行情,LUCID DIAGNOSTICS INC.股价,LUCID DIAGNOSTICS INC.股市,LUCID DIAGNOSTICS INC.股票价格,LUCID DIAGNOSTICS INC.股票交易,LUCID DIAGNOSTICS INC.股票购买,LUCID DIAGNOSTICS INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LUCID DIAGNOSTICS INC.(LUCD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction